Specialty code 183500000X · Santa Rosa, CA
NPI
1285704684
Since 2006
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
401 Bicentennial Way
Santa Rosa, CA, 95403
Phone (707) 571-3479
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$336K
2,019 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Amy C Le prescribed most often to Medicare patients was Atorvastatin Calcium, with 306 prescriptions and refills. In total Amy C Le wrote 2,019 Medicare prescriptions that cost $336K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-19.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 306 | 1,006 | 137 | $3,844 |
| Metformin Hcl Er Metformin Hcl | 206 | 662 | 93 | $2,111 |
| Ozempic Semaglutide | 134 | 136 | 29 | $99K |
| Metformin Hcl Generic | 128 | 427 | 56 | $1,716 |
| Jardiance Empagliflozin | 124 | 393 | 59 | $65K |
| Glipizide Generic | 117 | 378 | 64 | $1,418 |
| Humulin N Insulin Nph Human Isophane | 104 | 305 | 57 | $17K |
| Insulin Glargine-Yfgn Generic | 98 | 271 | 54 | $12K |
| Victoza 2-Pak Liraglutide | 74 | 75 | 15 | $46K |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 70 | 219 | 35 | $1,774 |
| Humulin R Insulin Regular, Human | 70 | 207 | 40 | $12K |
| Lisinopril Generic | 63 | 210 | 34 | $739 |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 52 | 133 | 32 | $1,297 |
| Losartan Potassium Generic | 51 | 170 | 25 | $601 |
| Liraglutide Generic | 37 | 37 | 13 | $26K |
Brand drugs: 746 claims; generic drugs: 1,099 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Amy C Le were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.